Abstract
There have been a number of significant recent developments in the recognition and management of depression in children. This paper draws on the 2004 National Institute for Health and Clinical Excellence guidelines, and advice about the use of selective serotonin reuptake inhibitors issued by the Committee on the Safety of Medicines in 2004, to review the treatment and management options for children and young people presenting with depressive disorders. There have been a number of significant recent developments in the recognition and management of depression in children. This paper draws on the 2004 National Institute for Health and Clinical Excellence guidelines, and advice about the use of selective serotonin reuptake inhibitors issued by the Committee on the Safety of Medicines in 2004, to review the treatment and management options for children and young people presenting with depressive disorders.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
